Company Overview and News
20h globenewswire - 1
NEW HAVEN, Conn., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. Dr. Zelenkofske will assume responsibility for the clinical development of Achillion’s oral factor D small molecule portfolio of compounds to treat complement-mediated diseases.
SGYP BSX SGYPW ACHN
Synergy has faced the daunting task of commercializing constipation drug Trulance via a risky go-it-alone strategy; initial efforts were ruinously expensive and yielded anemic prescription growth.
SGYP IRWD SGYPW SLUXF
2018-08-17 seekingalpha - 1
Ironwood Pharmaceuticals is a commercial biotechnology company focused on the treatment of gastrointestinal diseases, abdominal pain, and gout.
IRWD SGYP BIIB AGN AZN SGYPW SCMP SNY
2018-08-14 zacks - 1
On Aug 13, we issued an updated research report on Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) . This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of treatments primarily addressing gastrointestinal (“GI”) diseases. The company’s sole marketed drug, Linzess, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (“CIC”).
4503 IRWD SGYP ALPMY AZN AGN ALPMF AZN SGYPW
2018-08-08 zacks - 3
Synergy Pharmaceuticals (SGYP - Free Report) just came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.
SGYP KRO CIVI SGYPW SBOW
2018-07-27 zacks - 3
Investors in Synergy Pharmaceuticals Inc. (SGYP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 19, 2018 $1 Put had some of the highest implied volatility of all equity options today.
SGYP SGYPW TPH NVR TRN
2018-07-16 globenewswire - 1
WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations.
ABT SGYP SGYPW RDUS ABT
2018-07-06 zacks - 3
Investors in Synergy Pharmaceuticals Inc. (SGYP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $3.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
SGYP SGYPW ENPH
2018-06-18 seekingalpha - 1
Shareholders voted against the current board; they also voted down several proposals, including one to increase executive compensation and another that would have increased the number of authorized shares.
SGYP AGN SGYPW
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET